ReviewJournal of ophthalmology2026
Navigating the Core Challenges of Atropine Therapy in Myopia: A Mechanistic and Clinical Analysis of Dose, Response, and Durability.
Review in Journal of ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Biological mechanisms of atropine in myopia control (Review).Molecular medicine reports · 2026Pooled it
- Low-Dose Atropine and Other Interventions for Pediatric Myopia: A Systematic Review and Bayesian Network Meta-analysis of Efficacy and Post-treatment Outcomes.Ophthalmology and therapy · 2026Review
- Navigating the Core Challenges of Atropine Therapy in Myopia: A Mechanistic and Clinical Analysis of Dose, Response, and Durability.Journal of ophthalmology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myopia has emerged as a major global public health concern. Atropine, recognized as one of the foremost interventions for myopia control, has been validated for its efficacy and safety through a multitude of clinical studies. This article examines the most recent advancements in understanding atropine's mechanisms of action, optimizing dosage, customizing treatment plans, and assessing its long-term effectiveness in managing myopia. While atropine has shown impressive clinical results, there are still significant knowledge gaps surrounding its mechanisms of action, the personalization of treatments, rebound effects following cessation, and ocular side effects. Future investigations should prioritize clarifying the mechanisms of atropine, developing pertinent biomarkers for guiding individualized therapies, and investigating integrated control strategies that combine atropine with other treatments to enhance long-lasting therapeutic benefits. As a crucial medication for the prevention and management of myopia, atropine holds significant promise for a holistic approach to myopia treatment, offering new insights and directions to tackle this public health challenge.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.